GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dae Hwa Pharm Co Ltd (XKRX:067080) » Definitions » Debt-to-Revenue

Dae Hwa Pharm Co (XKRX:067080) Debt-to-Revenue : 0.62 (As of Dec. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Dae Hwa Pharm Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Dae Hwa Pharm Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩93,555 Mil. Dae Hwa Pharm Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩5,718 Mil. Dae Hwa Pharm Co's annualized Revenue for the quarter that ended in Dec. 2024 was ₩160,416 Mil. Dae Hwa Pharm Co's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.62.


Dae Hwa Pharm Co Debt-to-Revenue Historical Data

The historical data trend for Dae Hwa Pharm Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dae Hwa Pharm Co Debt-to-Revenue Chart

Dae Hwa Pharm Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.58 0.60 0.68 0.78 0.66

Dae Hwa Pharm Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.72 0.81 0.70 0.75 0.62

Competitive Comparison of Dae Hwa Pharm Co's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Dae Hwa Pharm Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dae Hwa Pharm Co's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dae Hwa Pharm Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Dae Hwa Pharm Co's Debt-to-Revenue falls into.


;
;

Dae Hwa Pharm Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Dae Hwa Pharm Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(93555.284 + 5718.407) / 149409.212
=0.66

Dae Hwa Pharm Co's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(93555.284 + 5718.407) / 160415.72
=0.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


Dae Hwa Pharm Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Dae Hwa Pharm Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Dae Hwa Pharm Co Business Description

Traded in Other Exchanges
N/A
Address
495 Hanu-ro, Hoengseong-eup, Hoengseong-gun, Seoul, Gangwon-do, KOR, 225-804
Dae Hwa Pharm Co Ltd is a specialized pharmaceutical company. It is mainly involved in manufacturing and distribution of pharmaceutical products. The company controls approximately 70% of the domestic transdermal drug delivery system market. The company offers analgesics and anti-inflammatory drugs, antihistamines, skeletal muscle relaxants, and cardiovascular drugs. Its products are exported to Asia, South America, Africa, and the Middle East.

Dae Hwa Pharm Co Headlines

No Headlines